Treatment of peritoneal carcinomatosis with hyperthermic intraperitoneal chemotherapy in colorectal cancer

ANZ J Surg. 2017 Sep;87(9):665-670. doi: 10.1111/ans.14077. Epub 2017 Jun 30.

Abstract

The peritoneum is the second most common site of metastasis after the liver and the only site of metastatic disease in approximately 25% of patients with colorectal cancer (CRC). In the past, peritoneal carcinomatosis in CRC was thought to be equivalent to distant metastasis; however, the transcoelomic spread of malignant cells is an acknowledged alternative pathway. Metastasectomy with curative intent is well accepted in patients with liver metastasis in CRC despite the paucity of randomized trials. Therefore, there is rationale for local treatment with peritonectomy to eliminate macroscopic disease, followed by hyperthermic intraperitoneal chemotherapy to destroy any residual free tumour cells within the peritoneal cavity. The aim of this paper is to summarize the current evidence for cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis in CRC.

Keywords: colorectal cancer; hyperthermic intraperitoneal chemotherapy; peritoneal carcinomatosis.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Trials, Phase II as Topic
  • Colorectal Neoplasms / complications
  • Colorectal Neoplasms / pathology*
  • Combined Modality Therapy / methods
  • Cytoreduction Surgical Procedures / methods
  • Humans
  • Hyperthermia, Induced / methods*
  • Peritoneal Neoplasms / diagnostic imaging
  • Peritoneal Neoplasms / mortality
  • Peritoneal Neoplasms / secondary*
  • Peritoneal Neoplasms / therapy*
  • Peritoneum / drug effects
  • Peritoneum / pathology*
  • Peritoneum / surgery
  • Randomized Controlled Trials as Topic
  • Survival Rate
  • Treatment Outcome